Related Experiment Videos
Review article: omeprazole and the cytochrome P450 system
1Institut für Pharmakologie und Toxikologie, RWTH Aachen, Germany.
Alimentary Pharmacology & Therapeutics
|February 1, 1995
Summary
Omeprazole interactions with cytochrome P450 enzymes show modest inhibition of subfamily 2C and minor induction of subfamily 1A. These effects on xenobiotic metabolism are unlikely to cause significant drug interactions or toxicity concerns.
Area of Science:
- Pharmacology
- Biochemistry
- Toxicology
Background:
- Cytochrome P450 enzymes are crucial for metabolizing foreign compounds (xenobiotics).
- Omeprazole, a proton pump inhibitor, interacts with these enzymes.
- Understanding these interactions is vital for drug safety and efficacy.
Purpose of the Study:
- To investigate the interactions between omeprazole and cytochrome P450 enzymes.
- To assess the clinical significance of these interactions on drug metabolism and toxicity.
Main Methods:
- Review of existing literature on omeprazole and cytochrome P450 interactions.
- Analysis of effects on specific enzyme subfamilies (CYP2C and CYP1A).
- Evaluation of impact on the metabolism of model drugs like diazepam and caffeine.
Main Results:
- Omeprazole exhibits modest inhibitory effects on CYP2C subfamily, leading to minor delays in the metabolism of certain drugs.
- Omeprazole shows minor induction of CYP1A subfamily, with limited impact on caffeine metabolism.
- Concerns regarding omeprazole-induced procarcinogen activation or increased acetaminophen toxicity are not supported by evidence.
Conclusions:
- Omeprazole's interactions with cytochrome P450 enzymes are generally modest and unlikely to cause significant clinical issues.
- The induction of CYP1A by omeprazole is minor and does not appear to increase cancer risk or drug toxicity.
- Dietary factors and lifestyle choices (e.g., cruciferous vegetables, smoking) have more substantial effects on P450 enzyme activity.